The survivin suppressant YM155 is a drug candidate for neuroblastoma. Here, we tested YM155 in 101 neuroblastoma cell lines (19 parental cell lines, 82 drug-adapted sublines). 77 cell lines displayed YM155 IC50s in the range of clinical YM155 concentrations. ABCB1 was an important determinant of YM155 resistance. The activity of the ABCB1 inhibitor zosuquidar ranged from being similar to that of the structurally different ABCB1 inhibitor verapamil to being 65-fold higher. ABCB1 sequence variations may be responsible for this, suggesting that the design of variantspecific ABCB1 inhibitors may be possible. Further, we showed that ABCC1 confers YM155 resistance. Previously, p53 depletion had resulted in decreased YM155 sensitivity. However, TP53-mutant cells were not generally less sensitive to YM155 than TP53 wild-type cells in this study. Finally, YM155 cross-resistance profiles differed between cells adapted to drugs as similar as cisplatin and carboplatin. In conclusion, the large cell line panel was necessary to reveal an unanticipated complexity of the YM155 response in neuroblastoma cell lines with acquired drug resistance. Novel findings include that ABCC1 mediates YM155 resistance and that YM155 crossresistance profiles differ between cell lines adapted to drugs as similar as cisplatin and carboplatin.
Introduction
Survivin is a potential drug target in cancer entities including neuroblastoma [1] [2] [3] [4] [5] [6] [7] , the most frequent solid extracranial paediatric cancer. About half of the patients are diagnosed with high-risk disease associated with overall survival rates below 50% despite myeloablative therapy and differentiation therapy using retinoids. While many neuroblastomas respond initially well to therapy, acquired drug resistance represents a major clinical problem [8, 9] . YM155 (sepantronium bromide) was introduced as a suppressor of survivin expression that displayed anti-cancer activity in pre-clinical models of different cancer entities including neuroblastoma [3] [4] [5] 7, 10] . However, DNA damage induction and Mcl-1 depletion were later suggested as additional or alternative anti-cancer mechanisms of YM155 [5, [11] [12] [13] [14] [15] . We recently confirmed that YM155 exerts its anti-neuroblastoma effects predominantly through survivin suppression [7] . YM155-induced survivin suppression proceeded DNA damage formation. Moreover, YM155 mimicked the effects of RNAi-mediated survivin depletion, whereas Mcl-1 depletion did not affect neuroblastoma cell viability [7] . Furthermore, YM155-adapted UKF-NB-3 neuroblastoma cells had developed resistance to RNAi-mediated survivin depletion [7] . We also investigated the effects of YM155 in neuroblastoma cells with acquired resistance to cisplatin, doxorubicin, or vincristine and detected in concert with previous findings reduced SLC35F2 (mediates cellular YM155 uptake) and increased ABCB1 (causes YM155 efflux) expression as drug-specific resistance mechanisms [3, 7, 16, 17] .
Our data further demonstrated that RNAi-mediated p53 depletion mediated resistance to YM155 and survivin depletion suggesting loss of p53 function to be a target-specific resistance mechanism that will affect all approaches that target survivin in neuroblastoma [7] .
Here, we investigated the effects of YM155 in a larger panel of 101 neuroblastoma cell lines that focused on acquired drug resistance containing 82 drugadapted neuroblastoma cell lines, which reflected resistance to 15 anti-cancer drugs. suspended in 200 µl resuspension buffer R including 2.5 µM siRNA. The electroporation was performed using two 20 millisecond pulses of 1400 V.
Subsequently, the cells were transferred into cell culture plates or flasks, containing pre-warmed cell culture medium.
TP53 sequencing
TP53 gene sequencing on cDNAs was performed using the following four pairs of primers: TP53 Ex2-3-f GTGACACGCTTCCCTGGAT and TP53 Ex2-3-r TCATCTGGACCTGGGTCTTC; TP53 Ex4-5-f CCCTTCCCAGAAAACCTACC and TP53
Ex4-5-r CTCCGTCATGTGCTGTGACT; TP53 EX6-7f
GTGCAGCTGTGGGTTGATT and TP53 Ex6-7r GGTGGTACAGTCAGAGCCAAC;
Tp53
Ex8-9-f CCTCACCATCATCACACTGG and TP53 Ex8-9-r GTCTGGTCCTGAAGGGTGAA. In addition all cell lines were examined for TP53 mutations by sequence analysis of genomic DNA as described previously [20] . PCR was performed as described before [20] . Each amplicon was sequenced bidirectionally.
Statistics
Results are expressed as mean ± S.D. of at least three experiments.
Comparisons between two groups were performed using Student's t-test. Three and more groups were compared by ANOVA followed by the Student-Newman-Keuls test. P values lower than 0.05 were considered significant.
Results

Effects of YM155 on the viability of parental neuroblastoma cell lines
YM155 was initially tested in a panel of 86 neuroblastoma cell lines consisting of 17 parental neuroblastoma cell lines and 69 drug-adapted sub-lines (Table S1 ). The IC50 values in the parental cell lines ranged from 0.49nM (UKF-NB-3) to 248nM (LAN-6) ( Figure 1 , Table S1 ). All parental cell lines despite from LAN-6, NB-S-124 (77nM), and SK-N-SH (75nM) had IC50 values in the range of clinical achievable YM155 plasma concentrations ( Figure 1A , Table S1 ) that were reported to reach up to 56nM [22] [23] [24] .
ABCB1-expressing neuroblastoma cell lines display low sensitivity to YM155
In concert with previous studies [3, 7] , ABCB1-expressing neuroblastoma cells displayed relatively low YM155 sensitivity and were (in contrast to low ABCB1expressing cells) sensitised to YM155 by verapamil and zosuquidar ( Figure 1B) , two structurally unrelated ABCB1 inhibitors [25] .
MYCN status does not influence neuroblastoma cell sensitivity to YM155
MYCN amplification is a major determinant of poor disease outcome in neuroblastoma [8, 9] . The YM155 IC50 ranged from 0.49nM (UKF-NB-3) to 77nM (NB-S-124) in MYCN-amplified cells and from 3.55nM (SK-N-AS) to 248nM (LAN-6) in not MYCN-amplified cells (Table S2 ). To exclude the effects of ABCB1, we compared the YM155 IC50 in cells with known MYCN status in the presence of the ABCB1 inhibitors verapamil and zosuquidar. In the presence of ABCB1 inhibitors, MYCN-amplified and non-MYC-amplified displayed a similar range of YM155 IC50s (Figure 2A , Table S2 ).
SH-EP-MYCN (TET21N) cells express a tetracycline-controllable MYCN transgene.
They display low MYCN levels in the presence of tetracycline antibiotics and high MYCN levels in the absence of tetracycline antibiotics [21] . SH-EP-MYCN (TET21N) cells displayed similar YM155 IC50 values in the absence or presence of doxycycline ( Figure 2B , Figure S1 ).
TP53 status does not predict neuroblastoma cell sensitivity to YM155
Previously, RNAi-mediated p53 depletion was shown to reduce the YM155 sensitivity of the neuroblastoma cell lines UKF-NB-3 and UKF-NB-6 [7] . However, the p53-null SK-N-AS cells displayed an YM155 IC50 of 3.55nM that was further reduced to 1.01nM and 1.31nM by verapamil and zosuquidar, respectively ( Figure 1 , Table S2 ).
Hence, SK-N-AS belongs in the presence of ABCB1 inhibitors to the most YM155sensitive neuroblastoma cell lines in the panel, despite the lack of functional p53.
To further investigate the relevance of the TP53 status for the neuroblastoma cell sensitivity to YM155, we determined YM155 IC50 values in a panel of 14 nutlin-3adapted TP53-mutant neuroblastoma cell lines [20, 26] . Our initial cell line panel (Table S1 ). In addition, we tested YM155 in nutlin-3-resistant, TP53 mutant sub-lines of two clonal p53 wild-type UKF-NB-3 sub-lines (UKF-NB-3clone1, UKF-NB-3clone3) and the TP53 wild-type neuroblastoma cell line UKF-NB-6 ( Figure 3 , Table S3 ). Only four out of the 14 nutlin-
3-resistant neuroblastoma cell lines displayed a >2-fold change in the YM155 IC50
relative to the respective parental cells, with 3.3 (UKF-NB-3clone1 r Nutlin 10µM I) being the highest fold change ( Figure 3 , Table S3 ). These findings do not suggest the cellular TP53 status to be a good predictor of neuroblastoma cell sensitivity to YM155.
Effects of YM155 on the viability of neuroblastoma cell lines with acquired drug resistance
In a panel of 69 sub-lines of the neuroblastoma cell lines IMR-5, IMR-32, NGP, NLF, SHEP, UKF-NB-2, UKF-NB-3, and UKF-NB-6 with acquired resistance to drug classes including platinum drugs, vinca alkaloids, taxanes, alkylating agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and nucleoside analogues (Table S1), resistance was commonly associated with decreased YM155 sensitivity.
However, 48 resistant cell lines displayed YM155 IC50 values in the range of therapeutic plasma levels (up to 56nM) (Table S1 ). (10%) resistant cell lines were more sensitive to YM155 than the respective parental cell lines (fold change <0.5) (Table S1 ). There were cell line-specific differences. For example, 8 out of 9 (89%) UKF-NB-3 sub-lines and 9 out of 10 (90%) UKF-NB-6 sublines, but only 2 out of 11 NLF sub-lines (18%) displayed cross-resistance to YM155 (Table S1 ).
The YM155 IC50 values in the drug-resistant cell lines ranged from 0.40nM (UKF-NB-3 r GEMCI 10 ) to 21,549nM (IMR-5 r DOCE 20 ) (Table S1 ). The mean YM155 IC50 values for the cell lines with resistance to different drug classes are presented in Figure   4A and Table S4 . The IC50 values for IMR-5 r DOCE 20 (21,549nM ) and UKF-NB-outliers that if included would not provide a proper representation of the overall data.
They are presented in Figure 4B , Table S1 , and Table S4 . IC50 values <56nM ( Figure 4B , Table S1 ).
For the topoisomerase II inhibitor (doxorubicin, etoposide)-and platinum drug (carboplatin, cisplatin, oxaliplatin)-adapted cell lines, we had sufficient data to perform drug-specific analyses. For six cell lines, we had doxorubicin-and etoposide-resistant sub-lines ( Figure 5A , Figure 5B , Table S1 ). To determine the mean YM155 IC50 value, we again removed the UKF-NB-3 sub-lines because of the high value of UKF-NB-3 r DOX 20 . Results revealed that acquired doxorubicin resistance resulted in a generally more pronounced YM155 resistance phenotype than acquired etoposide resistance ( Figure 5A , Figure 5B , Table S1 ).
In addition, the project cell line panel included carboplatin-, cisplatin-, and oxaliplatin-resistant sub-lines of five neuroblastoma cell lines ( Figure 5C , Figure 5D , Table S1 ). Cisplatin and oxaliplatin resistance were associated with a lower degree of YM155 resistance than carboplatin resistance ( Figure 5C , Figure 5D , Table S1 ).
Role of ABCB1 in the YM155 response of drug-adapted neuroblastoma cells
A significant amount of drug-adapted neuroblastoma cell lines displays increased ABCB1 activity [27] , and ABCB1 has been previously shown to mediate YM155 resistance [3, 7, 16] . In agreement with previous results, transduction of neuroblastoma cells with ABCB1 resulted in YM155 resistance, which was reduced by siRNA-mediated ABCB1 depletion ( Figure S2 ). Further, YM155 100nM, a concentration that did not induce survivin depletion in ABCB1-transduced UKF-NB-3
(UKF-NB-3 ABCB1 ) cells after 24h of incubation, reduced cellular survivin levels in UKF-NB-3 ABCB1 cells in the presence of the ABCB1 inhibitors verapamil and zosuquidar ( Figure S2 ).
Hence, we further examined the effects of verapamil and zosuquidar on YM155 sensitivity in a panel of 60 drug-adapted neuroblastoma cell lines (Table S5) Notably, the fold sensitisation by ABCB1 inhibitors was low (verapamil: 1.2-fold, zosuquidar: 1.5-fold) in NGP r ETO 400 , although the YM155 IC50s were reduced below 56nM. This suggests that ABCB1 expression is not a dominant YM155 resistance mechanism in NGP r ETO 400 cells (Table S5) .
IMR-5 r DOCE 20 , NGP r VCR 20 , and UKF-NB-2 r CARBO 2000 were sensitised by verapamil and zosuquidar to YM155. However, the effects of zosuquidar were more pronounced resulting in YM155 IC50 values below 56nM, whereas the YM155 IC50 values remained above 56nM in the presence of verapamil (Table S5 ). In NLF r DOX 40 and NLF r VINB 10 cells, zosuquidar (but not verapamil) increased the YM155 IC50 values by mechanisms that appear to be unrelated to ABCB1 (Table S5 ).
We selected two parental cell line/ drug-adapted subline pairs (IMR-5/ IMR-5 r DOCE 20 , IMR-32/ IMR-32 r DOX 20 ) for additional confirmatory experiments. The YM155 IC50s in these four cell lines in the absence and presence of zosuquidar determined MTT (used in the screen, measures oxidative phosphorylation in the mitochondria) were very similar to those determined by CellTiterGlo (alternative viability assay that measures ATP production) (Table S6 ). Both drug-adapted sublines displayed increased ABCB1 levels ( Figure S3 ). Moreover, YM155 500nM, a concentration that did not affect cellular survivin levels and PARP cleavage in IMR-5 r DOCE 20 cells after 24h incubation, caused survivin depletion and PARP cleavage in IMR-5 r DOCE 20 cells in the presence of the ABCB1 inhibitors verapamil and zosuquidar ( Figure S3 ).
YM155 is an ABCC1 substrate
NLF r VCR 10 cells were sensitised by verapamil but not by zosuquidar to YM155 (Table S5 ). NLF r VCR 10 cells are characterised by ABCC1 (also known as MRP1) expression but do not express ABCB1 [28]. Since only verapamil but not zosuquidar inhibits ABCC1 [29, 30] , this suggests that ABCC1 also mediates resistance to YM155.
In agreement, the ABCC1 inhibitor MK571 substantially reduced YM155 sensitivity in ABCC1-expressing NLF r VCR 10 cells but not in the parental NLF cell line that does not express ABCC1 (Table S7) .
Cross resistance to YM155 is caused by multiple resistance mechanisms in drug-adapted neuroblastoma cells
Although our data indicate that ABCB1 plays an important role in the cross- (Table S5) . Similarly, in 19 drug-adapted cell lines, the YM155 IC50 remained >2-fold higher in the presence of zosuquidar compared to the YM155 IC50 of the respective parental cell line in the presence of zosuquidar (Table S5 ). This included cell lines that were not sensitised by verapamil and/ or zosuquidar to YM155 and those that were sensitised to YM155 by verapamil and/ or zosuquidar but not to the level of the parental cells (Table S5 ).
Discrepancies in the effects of the ABCB1 inhibitors verapamil and zosuquidar on neuroblastoma cell sensitivity to YM155
Both, verapamil and zosuquidar, sensitised 25 of the drug-adapted cell lines to YM155 by >2-fold. There was an overlap of 23 cell lines that were sensitised to YM155 by both ABCB1 inhibitors by >2-fold (Table S5 ). Among the exceptions was the ABCC1-expressing cell line NLF r VCR 10 that has already been described above. (Table S5 ). The reasons for these differences remain unclear.
Since we had detected differences between the effects of the ABCB1 inhibitors verapamil and zosuquidar on the YM155 IC50 values in a number of cell lines, we compared both drugs in a wider panel of 74 cell lines ( Figure 6 , Table S5 ). In 45 cell lines, the YM155 IC50 values were in a similar range in the presence of verapamil and zosuquidar (YM155 IC50 in the presence of verapamil/ YM155 IC50 in the presence of zosuquidar >0.5 and <2.0). This included 33 cell lines that were neither sensitised to YM155 by verapamil nor by zosuquidar and 12 cell lines that were sensitised by verapamil and zosuquidar by more than 2-fold and in a similar fashion (Table S5 ).
13 cell lines were more strongly sensitised to YM155 by verapamil than by zosuquidar (YM155 IC50 in the presence of verapamil/ YM155 IC50 in the presence of zosuquidar <0.5). Only one of these cell lines (UKF-NB-6 r ETO 200 ) was sensitised by both verapamil and zosuquidar to YM155 by more than 2-fold. The remaining cell lines were either only sensitised to YM155 by more than 2-fold by verapamil and not by zosuquidar, or zosuquidar increased the YM155 IC50 by mechanisms that do not appear to be associated with effects on ABCB1 (Table S5 ).
16 cell lines were more strongly sensitised to YM155 by zosuquidar than by verapamil (YM155 IC50 in the presence of verapamil/ YM155 IC50 in the presence of zosuquidar >2.0). NGP r GEMCI 20 cells were only sensitised by zosuquidar to YM155
but not by verapamil. The other 15 of these cell lines were sensitised by more than 2fold to YM155 by both compounds with zosuquidar exerting more pronounced effects.
The relative differences between these two drugs on the YM155 sensitivity of these cell lines ranged from 2.2 (NLF r DOCE 20 , UKF-NB-3 r CARBO 2000 ) to 65.2 (UKF-NB-3 r DOCE 10 ) (Table S5) .
Discussion
YM155 has been suggested as therapeutic option for the treatment of neuroblastoma including therapy-refractory disease [3, 4, 7] . In a larger cell line panel, mainly consisting of neuroblastoma cell lines with acquired drug resistance, we here
show that 77 out of 101 tested neuroblastoma cell lines displayed YM155 IC50 values in the range of clinically achievable plasma concentrations up to 56 nM [22] [23] [24] .
Although MYCN amplification is a major indicator of poor prognosis in neuroblastoma [8, 9] , the efficacy of YM155 was independent of the MYCN status. As previously shown [3, 7, 16] , ABCB1-expressing cells displayed low YM155 sensitivity and were sensitised by the ABCB1 inhibitors verapamil and zosuquidar to YM155. The role of ABCB1 expression in neuroblastoma is not clear. ABCB1 expression at diagnosis is commonly regarded not to be of prognostic relevance [31], although ABCB1 expression has been reported in a significant fraction of patients [3, 32, 33] .
Notably, six (35%) out of the 17 parental neuroblastoma cell lines investigated in this study (Be(2)C, LAN-6, NB-S-124, SHEP, SK-N-AS, SK-N-SH) are characterised by ABCB1 activity, which is similar to a previous study, although there was some overlap between the cell line panels [3] . Limited information is available on ABCB1 expression as acquired drug resistance mechanism in neuroblastoma. Many drug-adapted neuroblastoma cell lines display enhanced ABCB1 activity [26, 34] , and drug-adapted cell lines have been shown to reflect clinically relevant resistance mechanisms [20, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . Some clinical hints may also point towards a role of ABCB1 in acquired resistance in neuroblastoma [33, 45] . Hence, ABCB1 may represent an acquired resistance mechanism in neuroblastoma.
In contrast to ABCB1, ABCC1 (also known as MRP1) is generally accepted as prognostic factor in neuroblastoma [24] . Interestingly, NLF r VCR 10 cells (that express zosuquidar efficacy over verapamil. Since zosuquidar is regarded as highly specific ABCB1 inhibitor [30, 46] , this difference seems to depend on discrepancies in the interaction with ABCB1. Notably, ABCB1 polymorphisms and mutations may substantially alter ABCB1 substrate specificity [47, 48] , which may explain the cell linespecific variation in the relative influence of zosuquidar and verapamil on ABCB1 function. Hence, it might be possible to design ABCB1 inhibitors that preferentially target specific ABCB1 variants. In this context, we have previously shown that certain ABCB1 inhibitors preferentially interfere with the ABCB1-mediated transport of certain ABCB1 substrates [49] .
Although RNAi-mediated p53 depletion decreases neuroblastoma cell sensitivity to YM155 as previously demonstrated [7] , For the topoisomerase II inhibitor-and platinum drug-adapted neuroblastoma cell lines, we could perform drug-specific sub-analyses. Among the topoisomerase II inhibitors, doxorubicin-resistant cells were more likely to be YM155-resistant than etoposide-resistant cells. This result may not be too surprising. Although doxorubicin and etoposide both inhibit the religation of the topoisomerase II cleavage complexes, they are structurally different compounds that differ in their exact interaction with this target and may exert additional varying effects [51] [52] [53] . Perhaps more strikingly, we also found differences among the carboplatin-, cisplatin-, and oxaliplatin-resistant cell lines. Carboplatin-resistant cells were more frequently YM155-resistant than cisplatin-or oxaliplatin-resistant cells. This is surprising because platinum drugs share a similar mechanism of action. In particular, the effects of carboplatin and cisplatin are thought to be much more related to each other than to oxaliplatin [54, 55] . The underlying reasons remain unclear, but the findings indicate substantial gaps in our understanding of the action of these frequently used drugs that need to be filled.
In conclusion, the investigation of YM155 in 101 neuroblastoma cell lines revealed complex sensitivity profiles and that larger panels of model systems are needed to uncover this complexity. Our findings confirm 1) that YM155 is a drug candidate for neuroblastoma including therapy-refractory disease with the majority of cell lines being sensitive to clinically achievable YM155 concentrations and 2) that ABCB1 is an important determinant of YM155 sensitivity. Notably, there were substantial differences in the relative efficacy of the ABCB1 inhibitors verapamil and zosuquidar in sensitising ABCB1-expressing cells to YM155. These differences may be caused by sequence variations in the transporters in the different cell lines, which suggests that it may be possible to design variant-specific ABCB1 inhibitors. Moreover, we present novel findings indicating 1) that YM155 resistance is also mediated by Table   S5 . concentrations that reduce neuroblastoma cell viability by 50% (IC50) as determined by MTT assay after a 5-day treatment period. Numerical data are presented in Table S3 . Values are presented as mean values over all cell lines from the individual groups.
There were no statistically significant differences. The cell lines UKF-NB-3 r DOX 20 and IMR-5 r DOCE 20 were not included into this analysis because they were regarded as outliers (please refer to the text). Numerical data are presented in Table S1 and Table S4 . 
